Details
Stereochemistry | EPIMERIC |
Molecular Formula | C29H34O6 |
Molecular Weight | 478.5767 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(OC(OCC)[C@H](O)[C@H]1OCC2=CC=CC=C2)[C@@H](COCC3=CC=CC=C3)OCC4=CC=CC=C4
InChI
InChIKey=ULLNJSBQMBKOJH-VIVFLBMVSA-N
InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1
Molecular Formula | C29H34O6 |
Molecular Weight | 478.5767 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
DOI:10.1159/000135957
http://www.rad-ar.or.jp/siori/print.cgi?n=14678
http://www.ncbi.nlm.nih.gov/pubmed/578928
Curator's Comment: description was created based on several sources, including:
DOI:10.1159/000135957
http://www.rad-ar.or.jp/siori/print.cgi?n=14678
http://www.ncbi.nlm.nih.gov/pubmed/578928
Tribenoside, a glucofuranoside derivative has been shown to have potent anti-allergic and anti-inflammatory properties. It has been reported to display a pluripotent antagonistic action against histamine, serotonin, bradykinin and other inflammatory substances. Tribenoside decrease capillary permeability, thus reducing edema. Tribenoside combat the pathological processes of capillaries and veins. It is used in adults and adolescents for treatment of venous circulation diseases. Although Tribenoside is derived from a sugar substance, it doesn’t affect the carbohydrate metabolism even in diabetics. Tribenoside might cause some side effects such as skin redness, headache. Very rare cases are: systemic anaphylaxis, including urticaria, angioedema.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Glyvenol Approved UseIt is also used in varicose syndrome (varicose veins). |
|||
Secondary | Glyvenol Approved UseIt is used as an adjunct in the treatment of phlebitis, periflebites and post-thrombotic syndrome before and after sclerotherapy of varicose veins. |
|||
Palliative | Glyvenol Approved UseIt is usually used in the treatment of bleeding, swelling associated with internal hemorrhoids. |
Sample Use Guides
Recommended dosage is of 1 dragee, 3 to 4 times a day (during or after meals). The daily dose (800 mg) should not be exceeded.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20118558
The expression of laminin alpha5 in the tribenoside-treated (at concentration 30uM) HaCaT cells was four times higher than that of control cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:50:40 GMT 2023
by
admin
on
Fri Dec 15 18:50:40 GMT 2023
|
Record UNII |
Z7N0Y673NU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC05AX05
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
||
|
WHO-ATC |
C05AX05
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
||
|
WHO-VATC |
QC05CX01
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
||
|
WHO-ATC |
C05CX01
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
||
|
NCI_THESAURUS |
C123418
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10310-32-4
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
233-687-2
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
DB13227
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
2730
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
2463
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
m11039
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID7023697
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
38557
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
Z7N0Y673NU
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
100000077513
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
C100302
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
C152735
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL3301681
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
196122
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
SUB11260MIG
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY | |||
|
TRIBENOSIDE
Created by
admin on Fri Dec 15 18:50:41 GMT 2023 , Edited by admin on Fri Dec 15 18:50:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
impurity C: not more than twice the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.5 per cent); if the area of the peak due to impurity C in the chromatogram obtained with the test solution is greater than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.25 per cent), dilute the test solution to obtain an area equal to or smaller than the area of the peak in the chromatogram obtained with reference solution (a); calculate the content of impurity C taking into account the dilution factor;
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |